Literature DB >> 1376185

Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants.

P R Henon1, H Liang, G Beck-Wirth, J C Eisenmann, M Lepers, E Wunder, G Kandel.   

Abstract

We studied hematopoietic and immune recovery in 40 subjects receiving autologous bone marrow (ABMT) or blood stem cell transplants (ABSCT). Supportive care, transplant-related morbidity, duration of hospitalization and cost were also considered. ABSCT was associated with more rapid recovery of all hematopoietic lineages than was ABMT. However, kinetics of immune recovery were similar between the groups. In the ABSCT group, there was a correlation between numbers of blood progenitor cells infused and the rate of hematopoietic recovery. The accelerated hematopoietic recovery following ABSCT correlated with less morbidity, fewer transfusions, briefer hospitalization and lower cost than ABMT.

Mesh:

Substances:

Year:  1992        PMID: 1376185

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  14 in total

1.  CD34+-selected autologous peripheral blood stem cell transplantation conditioned with total body irradiation for malignant lymphoma: increased risk of infectious complications.

Authors:  S Maeda; Y Kagami; M Ogura; H Taji; R Suzuki; E Kondo; S Asakura; T Takeuchi; K Miura; M Ando; S Nakamura; T Ito; T Kinoshita; R Ueda; Y Morishima
Journal:  Int J Hematol       Date:  2001-08       Impact factor: 2.490

2.  Significant mobilization of both conventional and regulatory T cells with AMD3100.

Authors:  Leslie S Kean; Sharon Sen; Olusegun Onabajo; Karnail Singh; Jennifer Robertson; Linda Stempora; Aylin C Bonifacino; Mark E Metzger; Daniel E L Promislow; Joseph J Mattapallil; Robert E Donahue
Journal:  Blood       Date:  2011-10-11       Impact factor: 22.113

3.  Storage of noncryopreserved periphered blood stem cells for transplantation.

Authors:  G Hechler; R Weide; J Heymanns; H Köppler; K Havemann
Journal:  Ann Hematol       Date:  1996-05       Impact factor: 3.673

Review 4.  Salvage Strategies for Management of Testicular Tumors.

Authors:  Smaranjit Chatterjee; Sudhir Kumar Rawal
Journal:  Indian J Surg Oncol       Date:  2017-06-06

5.  Immune reconstitution after autologous hematopoietic transplantation with Lin-, CD34+, Thy-1lo selected or intact stem cell products.

Authors:  Rakesh K Singh; Michelle L Varney; Cheryl Leutzinger; Julie M Vose; Philip J Bierman; Suleyman Buyukberber; Kazuhiko Ino; Kevin Loh; Craig Nichols; David Inwards; Robert Rifkin; James E Talmadge
Journal:  Int Immunopharmacol       Date:  2007-04-20       Impact factor: 4.932

6.  Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model.

Authors:  Lauri Burroughs; Marco Mielcarek; Marie-Térèse Little; Gary Bridger; Ron Macfarland; Simon Fricker; Jean Labrecque; Brenda M Sandmaier; Rainer Storb
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

7.  Phenotypic and functional comparison of mobilized peripheral blood versus umbilical cord blood megakaryocyte populations.

Authors:  Joshua Kellner; Sufang Li; Patrick A Zweidler-McKay; Elizabeth J Shpall; Ian McNiece
Journal:  Cytotherapy       Date:  2014-12-19       Impact factor: 5.414

8.  Evaluation of post-thaw CFU-GM: clinical utility and role in quality assessment of umbilical cord blood in patients receiving single unit transplant.

Authors:  Eiman Hussein; Todd DeFor; John E Wagner; Darin Sumstad; Claudio G Brunstein; David H McKenna
Journal:  Transfusion       Date:  2019-11-22       Impact factor: 3.157

9.  High-dose carboplatin, etoposide and melphalan (CEM) with peripheral blood progenitor cell support as late intensification for high-risk cancer: non-haematological, haematological toxicities and role of growth factor administration.

Authors:  P Benedetti Panici; L Pierelli; G Scambia; M L Foddai; M G Salerno; G Menichella; M Vittori; F Maneschi; U Caracussi; R Serafini; G Leone; S Mancuso
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Prophylactic ciprofloxacin treatment prevented high mortality, and modified systemic and intestinal immune function in tumour-bearing rats receiving dose-intensive CPT-11 chemotherapy.

Authors:  H Xue; C J Field; M B Sawyer; L A Dieleman; V E Baracos
Journal:  Br J Cancer       Date:  2009-04-28       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.